

Welcome to STN International! Enter x:x

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS				
NEWS	1		Web Page URLs for STN Seminar Schedule - N. America	
NEWS	2		"Ask CAS" for self-help around the clock	
NEWS	3	DEC 05	CASREACT(R) - Over 10 million reactions available	
NEWS	4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE	
NEWS	5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER	
NEWS	6	DEC 14	CA/CAPLUS to be enhanced with updated IPC codes	
NEWS	7	DEC 21	IPC search and display fields enhanced in CA/CAPLUS with the IPC reform	
NEWS	8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2	
NEWS	9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB	
NEWS	10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC	
NEWS	11	JAN 17	Pre-1988 INPI data added to MARPAT	
NEWS	12	JAN 17	IPC 8 in the WPI family of databases including WPIFV	
NEWS	13	JAN 30	Saved answer limit increased	
NEWS	14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA	

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 05:23:34 ON 11 FEB 2006

```
=> file medline, uspatful, dgene, embase, wpids, fsta, hcaplus, biosis, biotechds
COST IN U.S. DOLLARS          SINCE FILE          TOTAL
                                ENTRY          SESSION
```

FULL ESTIMATED COST

3.78

3.78

FILE 'MEDLINE' ENTERED AT 05:34:13 ON 11 FEB 2006

FILE 'USPATFULL' ENTERED AT 05:34:13 ON 11 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 05:34:13 ON 11 FEB 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 05:34:13 ON 11 FEB 2006
Copyright (c) 2006 Elsevier B.V./All rights reserved.

FILE 'WPIDS' ENTERED AT 05:34:13 ON 11 FEB 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 05:34:13 ON 11 FEB 2006
COPYRIGHT (C) 2006 International Food Information Service

FILE 'HCAPLUS' ENTERED AT 05:34:13 ON 11 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 05:34:13 ON 11 FEB 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 05:34:13 ON 11 FEB 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s solution formulation and shelf stable
L1 4 SOLUTION FORMULATION AND SHELF STABLE

=> s GLP or (glucagon-like-peptide)
L2 27364 GLP OR (GLUCAGON-LIKE-PEPTIDE)

=> s l2 and l1
L3 1 L2 AND L1

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 1 USPATFULL on STN
TI Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
AB A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:130729 USPATFULL
TITLE: Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
INVENTOR(S): Eliaz, Rom Ezer, Sunnyvale, CA, UNITED STATES
Zhang, Yuanpeng, Cupertino, CA, UNITED STATES
Rohloff, Catherine Many, Cupertino, CA, UNITED STATES
Weeks, Eric William, Oakland, CA, UNITED STATES
Junnarkar, Gunjan, Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005112188	A1	20050526
APPLICATION INFO.:	US 2004-988716	A1	20041115 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-520605P	20031117 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, PHILADELPHIA, PA, 19103, US	
NUMBER OF CLAIMS:	83	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	2028	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 05:23:34 ON 11 FEB 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, HCAPLUS, BIOSIS, BIOTECHDS' ENTERED AT 05:34:13 ON 11 FEB 2006

L1 4 S SOLUTION FORMULATION AND SHELF STABLE
L2 27364 S GLP OR (GLUCAGON-LIKE-PEPTIDE)
L3 1 S L2 AND L1

=> s 12 and formulation

L4 1968 L2 AND FORMULATION

=> s 14 and solution

L5 1528 L4 AND SOLUTION

=> s 15 and substitution

L6 0 L5 AND SUBSTITUTION

=> s 15 and (GLP analog)

L7 4 L5 AND (GLP ANALOG)

=> d 17 ti abs ibib tot

L7 ANSWER 1 OF 4 USPATFULL on STN

TI Use of **GLP** for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders

AB The present invention relates to methods for prevention and treatment of bone-related or nutrition-related disorders using a **GLP** molecule or **GLP** activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:69635 USPATFULL

TITLE: Use of **GLP** for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders

INVENTOR(S): Henriksen, Dennis B., Alleroed, DENMARK
Holst, Jens J., Hellerup, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004052862	A1	20040318
APPLICATION INFO.:	US 2003-393524	A1	20030320 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-954304, filed		

on 17 Sep 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-22844	20000918
	GB 2000-29920	20001207
	US 2002-371307P	20020410 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARDS & ANGELL, LLP, P.O. BOX 9169, BOSTON, MA, 02209	
NUMBER OF CLAIMS:	68	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	3496	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L7 ANSWER 2 OF 4 USPATFULL on STN

TI Process for solubilizing **glucagon-like peptide** lcompounds

AB Disclosed is a method of preparing a **GLP-1** compound that is soluble in aqueous **solution** at pH 7.4 from a **GLP-1** compound that is substantially insoluble in aqueous **solution** at pH 7.4. The insoluble **GLP-1** compound is dissolved in aqueous base or in aqueous acid to form a **GLP-1 solution**. The **GLP-1 solution** is then neutralized to a pH at which substantially no amino acid racemization of the **GLP-1** compounds occurs, after which the soluble **GLP-1** compound is isolated from the neutralized **solution**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:86804 USPATFULL
TITLE: Process for solubilizing **glucagon-like peptide** lcompounds
INVENTOR(S): Prouty, Walter Francis, JR., Indianapolis, IN, UNITED STATES
Rinella, Joseph Vincent, JR., Ypsilanti, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060412	A1	20030327
APPLICATION INFO.:	US 2002-169657	A1	20020628 (10)
	WO 2001-US10		20010116
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	1103		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L7 ANSWER 3 OF 4 USPATFULL on STN

TI Use of **GLP** for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders

AB The present invention relates to methods for prevention and treatment of bone-related or nutrition-related disorders using a **GLP** molecule or **GLP** activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of

the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:67183 USPATFULL
TITLE: Use of GLP for the treatment, prevention,
diagnosis, and prognosis of bone-related and
nutrition-related disorders
INVENTOR(S): Henriksen, Dennis Bang, Alleroed, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037836	A1	20020328
	US 6770620	B2	20040803
APPLICATION INFO.:	US 2001-954304	A1	20010918 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-22844	20000918
	GB 2000-29920	20001207
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711	
NUMBER OF CLAIMS:	57	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2814	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 4 USPATFULL on STN

TI GLP-1 analogs useful for diabetes treatment
AB The invention provides effective analogs of the active GLP-1 peptides, 7-34, 7-35, 7-36, and 7-37, which have improved characteristics for treatment of diabetes Type II. These analogs have amino acid substitutions at positions 7-10 and/or are truncated at the C-terminus and/or contain various other amino acid substitutions in the basic peptide. The analogs may either have an enhanced capacity to stimulate insulin production as compared to glucagon or may exhibit enhanced stability in plasma as compared to GLP-1 (7-37) or both. Either of these properties will enhance the potency of the analog as a therapeutic. Analogs having D-amino acid substitutions in the 7 and 8 positions and/or N-alkylated or N-acylated amino acids in the 7 position are particularly resistant to degradation in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:72866 USPATFULL
TITLE: GLP-1 analogs useful for diabetes treatment
INVENTOR(S): Buckley, Douglas I., 215 Brookward Rd., Woodside, CA, United States 94062
Habener, Joel F., 217 Plymouth Rd., Newton Highlands, MA, United States 02161
Mallory, Joanne B., 199 Acalanes, Apt. 3, Sunnyvale, CA, United States 94086
Mojsov, Svetlana, 504 E. 63rd St., New York, NY, United States 10021

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5545618		19960813
APPLICATION INFO.:	US 1993-165516		19931210 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-762768, filed on 20 Sep 1991 which is a continuation-in-part of Ser. No. US 1990-468736, filed on 24 Jan 1990, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Prickril, Benet
LEGAL REPRESENTATIVE: Morrison & Foerster
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1062
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 05:23:34 ON 11 FEB 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, HCAPLUS, BIOSIS, BIOTECHDS' ENTERED AT 05:34:13 ON 11 FEB 2006

L1 4 S SOLUTION FORMULATION AND SHELF STABLE
L2 27364 S GLP OR (GLUCAGON-LIKE-PEPTIDE)
L3 1 S L2 AND L1
L4 1968 S L2 AND FORMULATION
L5 1528 S L4 AND SOLUTION
L6 0 S L5 AND SUBSTITUTION
L7 4 S L5 AND (GLP ANALOG)

=> s 15 and diabetes

L8 1086 L5 AND DIABETES

=> s 18 and treatment

L9 974 L8 AND TREATMENT

=> s 19 and amide forms

L10 3 L9 AND AMIDE FORMS

=> d l10 ti abs ibib tot

L10 ANSWER 1 OF 3 USPATFULL on STN

TI Method for administering insulintropic peptides

AB The claimed invention relates to a method of administering **glucagon-like peptide-1** molecules by inhalation, a method for treating **diabetes** by administering **glucagon-like peptide-1** molecules by inhalation, and a method for treating hyperglycemia by administering **glucagon-like peptide-1** molecules by inhalation.

Inhalant

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:158101 USPATFULL

TITLE: Method for administering insulintropic peptides

INVENTOR(S): Hughes, Benjamin Lee, Indianapolis, IN, UNITED STATES
Wolff, Ronald Keith, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004120897	A1	20040624
APPLICATION INFO.:	US 2003-732091	A1	20031210 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-383789, filed on 26 Aug 1999, GRANTED, Pat. No. US 6720407		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-98273P	19980828 (60)

US 1998-100012P 19980911 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288,
INDIANAPOLIS, IN, 46206-6288
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 985
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 3 USPATFULL on STN

TI Method for administering insulinotropic peptides
AB The claimed invention relates to a method of administering
glucagon-like peptide-1 molecules by
inhalation, a method for treating **diabetes** by administering
glucagon-like peptide-1 molecules by
inhalation, and a method for treating hyperglycemia by administering
glucagon-like peptide-1 molecules by
inhalation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:90699 USPATFULL
TITLE: Method for administering insulinotropic peptides
INVENTOR(S): Hughes, Benjamin Lee, Indianapolis, IN, United States
Wolff, Ronald Keith, Carmel, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6720407	B1	20040413
APPLICATION INFO.:	US 1999-383789		19990826 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-100012P	19980911 (60)
	US 1998-98273P	19980828 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Lukton, David
LEGAL REPRESENTATIVE: Cox, Gregory A.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1011
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 3 USPATFULL on STN

TI Modified transferrin fusion proteins
AB Modified fusion proteins of transferrin and therapeutic proteins or
peptides including soluble toxin receptors, with increased serum
half-life or serum stability are disclosed. Preferred fusion proteins
include those modified so that the transferrin moiety exhibits no or
reduced glycosylation, binding to iron and/or binding to the transferrin
receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:313593 USPATFULL
TITLE: Modified transferrin fusion proteins
INVENTOR(S): Prior, Christopher P., King of Prussia, PA, UNITED
STATES
Lai, Chay-Huei, King of Prussia, PA, UNITED STATES

PATENT ASSIGNEE(S): Sadeghi, Homayoun, King of Prussia, PA, UNITED STATES
Turner, Andrew, King of Prussia, PA, UNITED STATES
BIOREXIS PHARMACEUTICAL CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003221201	A1	20031127
APPLICATION INFO.:	US 2003-378094	A1	20030304 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-231494, filed on 30 Aug 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-315745P	20010830 (60)
	US 2001-334059P	20011130 (60)
	US 2002-406977P	20020830 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	5075	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> dhis
DHIS IS NOT A RECOGNIZED COMMAND.
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 05:23:34 ON 11 FEB 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, HCAPLUS, BIOSIS, BIOTECHDS' ENTERED AT 05:34:13 ON 11 FEB 2006

L1	4 S SOLUTION FORMULATION AND SHELF STABLE
L2	27364 S GLP OR (GLUCAGON-LIKE-PEPTIDE)
L3	1 S L2 AND L1
L4	1968 S L2 AND FORMULATION
L5	1528 S L4 AND SOLUTION
L6	0 S L5 AND SUBSTITUTION
L7	4 S L5 AND (GLP ANALOG)
L8	1086 S L5 AND DIABETES
L9	974 S L8 AND TREATMENT
L10	3 S L9 AND AMIDE FORMS

=> e brader, m/au

E1	2	BRADER WILBUR THOMAS/AU
E2	1	BRADER WILLIAM R/AU
E3	0 -->	BRADER, M/AU
E4	1	BRADERING D/AU
E5	1	BRADERMAN GRETCHEN/AU
E6	3	BRADERSEN H/AU
E7	2	BRADERSEN HANS JURGEN/AU
E8	2	BRADERSEN UDO/AU
E9	1	BRADES C H/AU
E10	1	BRADES D L/AU
E11	1	BRADES J M/AU
E12	1	BRADESCO F/AU

=> s 18 and preservative
L11 256 L8 AND PRESERVATIVE

=> s 111 and (tonicity modifier)
L12 2 L11 AND (TONICITY MODIFIER)

=> d 112 ti abs ibib tot

L12 ANSWER 1 OF 2 USPATFULL on STN

TI Stable **formulation** of modified GLP-1

AB Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:173886 USPATFULL

TITLE: Stable **formulation** of modified GLP-1

INVENTOR(S): Flink, James M., Klampenborg, DENMARK
Larsen, Silke Moller, Charlottenlund, DENMARK
Jensen, Simon Bjerregaard, Frederiksberg, DENMARK
Engelund, Dorte Kot, Holte, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119734	A1	20030626
APPLICATION INFO.:	US 2002-185923	A1	20020627 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-1010	20010628
	DK 2001-1053	20010704
	DK 2002-93	20020118
	DK 2001-1011	20010628
	DK 2001-1052	20010704
	DK 2002-92	20020118
	US 2001-308325P	20010727 (60)
	US 2001-308297P	20010727 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk of North America, Inc.,
Suite 6400, 405 Lexington Avenue, New York, NY,
10174-6401

NUMBER OF CLAIMS: 25

EXEMPLARY CLAIM: 1

LINE COUNT: 2061

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 2 USPATFULL on STN

TI Peptide pharmaceutical formulations

AB A pharmaceutical composition for administration to a mammal is disclosed. The composition includes a therapeutically effective amount of a peptide, such as a GLP-1 molecule, a PTH molecule, or a GRF molecule. The composition further includes a buffer including a weak acid having an acid dissociation constant value of greater than about 1+10.sup.-5, such as acetic acid. The composition also includes an excipient for making the composition generally isotonic, such as D-mannitol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:119850 USPATFULL

TITLE: Peptide pharmaceutical formulations

INVENTOR(S): Holmquist, Barton, Lincoln, NE, UNITED STATES

Dormady, Daniel C., Omaha, NE, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061838	A1	20020523
APPLICATION INFO.:	US 2001-858880	A1	20010517 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205377P	20000517 (60)
	US 2000-205262P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Beth A. Burrous, FOLEY & LARDNER, Suite 500, 3000 K Street, N.W., Washington, DC, 20007-5109	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	929	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 05:23:34 ON 11 FEB 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, HCAPLUS, BIOSIS, BIOTECHDS' ENTERED AT 05:34:13 ON 11 FEB 2006

L1 4 S SOLUTION FORMULATION AND SHELF STABLE
L2 27364 S GLP OR (GLUCAGON-LIKE-PEPTIDE)
L3 1 S L2 AND L1
L4 1968 S L2 AND FORMULATION
L5 1528 S L4 AND SOLUTION
L6 0 S L5 AND SUBSTITUTION
L7 4 S L5 AND (GLP ANALOG)
L8 1086 S L5 AND DIABETES
L9 974 S L8 AND TREATMENT
L10 3 S L9 AND AMIDE FORMS
E BRADER, M/AU
L11 256 S L8 AND PRESERVATIVE
L12 2 S L11 AND (TONICITY MODIFIER)

=> s l11 and glycerin

L13 111 L11 AND GLYCERIN

=> s l13 and (m-cresol)

L14 26 L13 AND (M-CRESOL)

=> d l14 ti abs ibib tot

L14 ANSWER 1 OF 26 USPATFULL on STN

TI Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof

AB Fatty acid compositions for administration of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about

10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.

ACCESSION NUMBER: 2006:21042 USPATFULL
TITLE: Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof
INVENTOR(S): Radhakrishnan, Balasingam; Chapel Hill, NC, UNITED STATES
Aggarwal, Diti, Raleigh, NC, UNITED STATES
Ferro, Michelle, Raleigh, NC, UNITED STATES
James, Kenneth D., Mebane, NC, UNITED STATES
Malkar, Navdeep B., Cary, NC, UNITED STATES
Miller, Mark A., Raleigh, NC, UNITED STATES
Pavliv, Leo, Morrisville, NC, UNITED STATES
Polowy, Karen, Raleigh, NC, UNITED STATES
Puskas, Monica, Spring Hope, NC, UNITED STATES
Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006018874	A1	20060126
APPLICATION INFO.:	US 2005-184528	A1	20050719 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-589058P	20040719 (60)
	US 2004-619153P	20041015 (60)
	US 2004-632578P	20041202 (60)
	US 2005-655838P	20050224 (60)
	US 2005-655803P	20050224 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MOORE & VAN ALLEN PLLC, P.O. BOX 13706, Research Triangle Park, NC, 27709, US
NUMBER OF CLAIMS: 111
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 42 Drawing Page(s)
LINE COUNT: 5677

L14 ANSWER 2 OF 26 USPATFULL on STN
TI Prolonged delivery of peptides
AB There are disclosed methods for the treatment of non-insulin dependent **diabetes** mellitus in a mammal comprising the prolonged administration of **GLP-1** (7-37), and related peptides. Also disclosed are compositions to prolong the administration of the peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:4460 USPATFULL
TITLE: Prolonged delivery of peptides
INVENTOR(S): Kim, Yesook, Branford, CT, UNITED STATES
Lambert, William J., East Lyme, CT, UNITED STATES
Qi, Hong, East Lyme, CT, UNITED STATES
Gelfand, Robert A., Madison, CT, UNITED STATES
Geoghegan, Kieran F., Mystic, CT, UNITED STATES
Danley, Dennis E., Waterford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006003918	A1	20060105
APPLICATION INFO.:	US 2004-6990	A1	20041207 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-943084, filed on 31		

Aug 2001, GRANTED, Pat. No. US 6828303 Continuation of
Ser. No. US 1995-472349, filed on 7 Jun 1995, GRANTED,
Pat. No. US 6284727 Continuation of Ser. No. US
1994-181655, filed on 25 Jan 1994, ABANDONED
Continuation-in-part of Ser. No. US 1993-44133, filed
on 7 Apr 1993, ABANDONED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 12531 HIGH BLUFF DRIVE, SUITE
100, SAN DIEGO, CA, 92130-2040, US
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 2264
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 26 USPATFULL on STN

TI Intranasal administration of glucose-regulating peptides
AB Pharmaceutical compositions and methods are described comprising at
least one glucose-regulating peptide, such as amylin, **glucagon**
-like peptide-1 (GLP), pramlintide or
exendin-4 and one or more mucosal delivery-enhancing agents for enhanced
nasal mucosal delivery of the amylin, for treating a variety of diseases
and conditions in mammalian subjects, including obesity and
diabetes mellitus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:165878 USPATFULL
TITLE: Intranasal administration of glucose-regulating
peptides
INVENTOR(S): Quay, Steven C., Edmonds, WA, UNITED STATES
Costantino, Henry R., Woodinville, WA, UNITED STATES
PATENT ASSIGNEE(S): Natestch Pharmaceutical Company Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005143303	A1	20050630
APPLICATION INFO.:	US 2004-991597	A1	20041118 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-532337P	20031226 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Natestch Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906, US	
NUMBER OF CLAIMS:	103	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	4420	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 26 USPATFULL on STN

TI Biphasic mixtures of **glp-1** and insulin
AB The present invention encompasses pharmaceutical formulations comprising
a biphasic mixture which comprises a **glucagon like**
peptide (GLP-1) compound in a solid phase and an
insulin in a **solution** phase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:321453 USPATFULL
TITLE: Biphasic mixtures of **glp-1** and insulin
INVENTOR(S): DeFelippis, Michael Rosario, Carmel, IN, UNITED STATES

DiMarchi, Richard Dennis, Carmel, IN, UNITED STATES
Ng, Kingman, Carmel, IN, UNITED STATES
Trautmann, Michael Ernst, Hamburg, GERMANY, FEDERAL
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004254107	A1	20041216
APPLICATION INFO.:	US 2004-490575	A1	20040319 (10)
	WO 2002-US29842		20021007

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-350676P	20011019 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gregory A Cox, Eli Lilly & Company, Patent Division, PO Box 6288, Indianapolis, IN, 46206-6288	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1679	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 5 OF 26 USPATFULL on STN
TI Pre-mixes of **glp-1** and basal insulin
AB The present invention encompasses pre-mixed formulations comprising a
GLP-1 polypeptide and a basal insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:299841 USPATFULL
TITLE: Pre-mixes of **glp-1** and basal insulin
INVENTOR(S): DeFelippis, Michael Rosario, Carmel, IN, UNITED STATES
DiMarchi, Richard Dennis, Carmel, IN, UNITED STATES
Ng, Kingman, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004235710	A1	20041125
APPLICATION INFO.:	US 2004-486333	A1	20040209 (10)
	WO 2002-US21856		20020823

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-60315460	20010828
	US 2002-60385266	20020531
	US 2002-60386061	20020604
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	2056	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 6 OF 26 USPATFULL on STN
TI Preparation and use of aryl alkyl acid derivatives for the treatment of
obesity
AB This invention relates to certain aryl alkyl acid compounds,
compositions, and methods for treating or preventing obesity and related
diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:286829 USPATFULL
TITLE: Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
INVENTOR(S): Smith, Roger, Madison, CT, UNITED STATES
Campbell, Ann-Marie, Monroe, CT, UNITED STATES
Coish, Philip, New Haven, CT, UNITED STATES
Dai, Miào, Briarwood, NY, UNITED STATES
Jenkins, Susan, Milford, CT, UNITED STATES
Lowe, Derek, Hamden, CT, UNITED STATES
O'Connor, Stephen, Guilford, CT, UNITED STATES
Su, Ning, Hamden, CT, UNITED STATES
Wang, Gan, Wallingford, CT, UNITED STATES
Zhang, Mingbao, Stamford, CT, UNITED STATES
Zhu, Lei, Milford, CT, UNITED STATES
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, West Haven, CT (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004224997	A1	20041111
APPLICATION INFO.:	US 2004-839833	A1	20040506 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-469619P	20030509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5225	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 7 OF 26 USPATFULL on STN

TI Compounds for protein stabilization and methods for their use
AB The present invention is directed to stabilized polypeptide compositions. Typical embodiments of the present invention provide improved methods and materials for maintaining the stability of insulin polypeptide formulations. In particular, the disclosure provided herein teaches that the aggregation of insulin polypeptides can be inhibited by combining them with a class of compounds having the general formula A.sup.1--L.sup.1--S--L.sup.2--A.sup.2, wherein S comprises from one to seven consecutive atoms selected from the group consisting of nitrogen, carbon, and oxygen, wherein at least one of the atoms is a carbon atom; L.sup.1 and L.sup.2 are linking groups having from two to twelve atoms selected from the group consisting of nitrogen, carbon, oxygen, sulfur, and phosphorus; and A.sup.1 and A.sup.2 are carboxylic acid groups.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:221747 USPATFULL
TITLE: Compounds for protein stabilization and methods for their use
INVENTOR(S): Van Antwerp, William Peter, Valencia, CA, UNITED STATES
Walsh, Joseph C., Pacific Palisades, CA, UNITED STATES
PATENT ASSIGNEE(S): Medtronic MiniMed, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171518	A1	20040902
APPLICATION INFO.:	US 2003-375383	A1	20030227 (10)
DOCUMENT TYPE:	Utility		

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GATES & COOPER LLP, HOWARD HUGHES CENTER, 6701 CENTER
DRIVE WEST, SUITE 1050, LOS ANGELES, CA, 90045
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 8 OF 26 USPATFULL on STN

TI Amidated **glucagon-like peptide-1**

AB The present invention encompasses a **GLP-1** analog and compositions and formulations thereof useful for the treatment of hyperglycemia and other various diseases and conditions in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:172483 USPATFULL

TITLE: Amidated **glucagon-like peptide-1**

INVENTOR(S): DiMarchi, Richard Dennis, Carmel, IN, UNITED STATES
Millican Jr, Rohn Lee, Indianapolis, IN, UNITED STATES
Glaesner, Wolfgang, Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004132647	A1	20040708
APPLICATION INFO.:	US 2003-450042	A1	20030610 (10)
	WO 2001-US43167		20011130
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Mark J Stewart, Eli Lilly & Company, Patent Division, PO Box 6288, Indianapolis, IN, 46206-6288		
NUMBER OF CLAIMS:	40		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1338		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 9 OF 26 USPATFULL on STN

TI Method for administering insulintropic peptides

AB The claimed invention relates to a method of administering **glucagon-like peptide-1** molecules by inhalation, a method for treating **diabetes** by administering **glucagon-like peptide-1** molecules by inhalation, and a method for treating hyperglycemia by administering **glucagon-like peptide-1** molecules by inhalation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:158101 USPATFULL

TITLE: Method for administering insulintropic peptides

INVENTOR(S): Hughes, Benjamin Lee, Indianapolis, IN, UNITED STATES
Wolff, Ronald Keith, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004120897	A1	20040624
APPLICATION INFO.:	US 2003-732091	A1	20031210 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-383789, filed on 26 Aug 1999, GRANTED, Pat. No. US 6720407		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-98273P	19980828 (60)

US 1998-100012P 19980911 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288,
INDIANAPOLIS, IN, 46206-6288
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 985
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 10 OF 26 USPATFULL on STN
TI Method for administering insulintropic peptides
AB The claimed invention relates to a method of administering
glucagon-like peptide-1 molecules by
inhalation, a method for treating **diabetes** by administering
glucagon-like peptide-1 molecules by
inhalation, and a method for treating hyperglycemia by administering
glucagon-like peptide-1 molecules by
inhalation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:90699 USPATFULL
TITLE: Method for administering insulintropic peptides
INVENTOR(S): Hughes, Benjamin Lee, Indianapolis, IN, United States
Wolff, Ronald Keith, Carmel, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6720407	B1	20040413
APPLICATION INFO.:	US 1999-383789		19990826 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-100012P	19980911 (60)
	US 1998-98273P	19980828 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Lukton, David	
LEGAL REPRESENTATIVE:	Cox, Gregory A.	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1011	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L14 ANSWER 11 OF 26 USPATFULL on STN
TI Chronic treatment regimen using glucagon-like insulintropic peptides
AB The present invention encompasses a method of treating a disease by
maintaining chronic steady state serum levels of a **GLP-1**
compound within a specified range.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:70591 USPATFULL
TITLE: Chronic treatment regimen using glucagon-like
insulintropic peptides
INVENTOR(S): Dodd, Steven Witt, Zionsville, IN, UNITED STATES
Mace, Kenneth Francis, Fishers, IN, UNITED STATES
Trautmann, Michael Ernst, Hamburg, GERMANY, FEDERAL
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004053819	A1	20040318
APPLICATION INFO.:	US 2003-450124	A1	20030610 (10)
	WO 2001-US44698		20011207
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Page(s)		
LINE COUNT:	1857		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L14 ANSWER 12 OF 26 USPATFULL on STN

TI Polypeptide compositions with improved stability

AB The present invention provides means to improve the chemical stability of aqueous, parenteral pharmaceutical compositions comprising a polypeptide and **glycerin**. Reactive aldehydes are identified in commercial glycerins, and means for reducing such are provided. Convenient means are provided to assay for reactive aldehydes in **glycerin**, and a strong linear correlation between the level of reactive aldehydes in **glycerin** and chemical stability of compositions comprising a polypeptide and **glycerin** is demonstrated. The invention includes aqueous compositions comprising a polypeptide and **glycerin** having improved chemical stability compared to compositions previously known.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:294785 USPATFULL

TITLE: Polypeptide compositions with improved stability

INVENTOR(S): DeFelippis, Michael Rosario, Carmel, IN, UNITED STATES
Dobbins, Michael Allen, Lebanon, IN, UNITED STATES
Sharknas, Alby David, Indianapolis, IN, UNITED STATES
Prokai, Alex Mark, Carmel, IN, UNITED STATES
Rinella, Joseph Vincent, Ypsilanti, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207802	A1	20031106
APPLICATION INFO.:	US 2002-130836	A1	20020521 (10)
	WO 2000-US32421		20001205

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-377208	19991228
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	2094	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L14 ANSWER 13 OF 26 USPATFULL on STN

TI Protein formulations

AB The present invention discloses a stable, soluble **formulation** comprising a medically useful peptide or protein, a hydrophobic **preservative**, and nicotinamide. Said storage-stable, soluble **formulation** is useful as a multi-use pharmaceutical product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100072 USPATFULL
TITLE: Protein formulations
INVENTOR(S): Rinella, Vincent Joseph, JR., Brownsburg, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069182	A1	20030410
	US 6573237	B2	20030603
APPLICATION INFO.:	US 2002-170301	A1	20020612 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-787500, filed on 16 Mar 2001, GRANTED, Pat. No. US 6440930		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	700		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 14 OF 26 USPATFULL on STN

TI Prolonged delivery of peptides

AB There are disclosed methods for the treatment of non-insulin dependent **diabetes** mellitus in a mammal comprising the prolonged administration of **GLP-1** (7-37), and related peptides. Also disclosed are compositions to prolong the administration of the peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:71950 USPATFULL
TITLE: Prolonged delivery of peptides
INVENTOR(S): Kim, Yesook, Branford, CT, UNITED STATES
Lambert, William J., East Lyme, CT, UNITED STATES
Qi, Hong, East Lyme, CT, UNITED STATES
Gelfand, Robert A., Madison, CT, UNITED STATES
Geoghegan, Kieran F., Mystic, CT, UNITED STATES
Danley, Dennis E., Waterford, CT, UNITED STATES
PATENT ASSIGNEE(S): Scios Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003050237	A1	20030313
	US 6828303	B2	20041207
APPLICATION INFO.:	US 2001-943084	A1	20010831 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-472349, filed on 7 Jun 1995, PATENTED Continuation-in-part of Ser. No. US 1993-44133, filed on 7 Apr 1993, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934		
NUMBER OF CLAIMS:	48		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Page(s)		
LINE COUNT:	3046		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 15 OF 26 USPATFULL on STN

TI **Glucagon-like peptide-1** crystals

AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of **glucagon-like peptide** -1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating **diabetes**, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:65340 USPATFULL

TITLE: **Glucagon-like peptide-1** crystals

INVENTOR(S): Hermeling, Ronald Norbert, Indianapolis, IN, UNITED STATES
Hoffmann, James Arthur, Greenwood, IN, UNITED STATES
Narasimhan, Chakravarthy, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045464	A1	20030306
	US 6555521	B2	20030429
APPLICATION INFO.:	US 2001-997792	A1	20011130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-209799, filed on 11 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69728P	19971216 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, DROP CODE 1104, INDIANAPOLIS, IN, 46285	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1128	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 16 OF 26 USPATFULL on STN

TI **GLP-1** formulations

AB Methods and formulations are presented that provide for a) the oral absorption of **GLP-1** peptides that bind surfactants; and b) long-term storage of formulations containing these peptides. For example, a **GLP-1**/DSS complex is administered orally instead of parenterally, which is much more convenient for, and facilitates compliance with diabetic patients and persons with other **GLP-1** treated conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:228306 USPATFULL

TITLE: **GLP-1** formulations

INVENTOR(S): Hoffmann, James Arthur, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002123466	A1	20020905
APPLICATION INFO.:	US 2002-72540	A1	20020208 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-573809, filed on 18 May 2000, GRANTED, Pat. No. US 6410513 Continuation of Ser. No. WO 1998-US25515, filed on 2 Dec 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67600P	19971205 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288,
INDIANAPOLIS, IN, 46206-6288
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 546
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 17 OF 26 USPATFULL on STN

TI Protein formulations
AB The present invention discloses a stable, soluble **formulation** comprising a medically useful peptide or protein, a hydrophobic **preservative**, and nicotinamide. Said storage-stable, soluble **formulation** is useful as a multi-use pharmaceutical product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:217237 USPATFULL
TITLE: Protein formulations
INVENTOR(S): Rinella, Jr., Vincent Joseph, Brownsburg, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6440930	B1	20020827
	WO 2000015224		20000323
APPLICATION INFO.:	US 2001-787500		20010316 (9)
	WO 1999-US21055		19990914
			20010316 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-100687P	19980917 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Henley, III, Raymond	
LEGAL REPRESENTATIVE:	Stewart, Mark J., Davis, Paula K.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	715	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 18 OF 26 USPATFULL on STN

TI **GLP-1** formulations
AB Methods and formulations are presented that provide for a) the oral absorption of **GLP-1** peptides that bind surfactants; and b) long-term storage of formulations containing these peptides. For example, a **GLP-1**/DSS complex is administered orally instead of parenterally, which is much more convenient for, and facilitates compliance with diabetic patients and persons with other **GLP-1** treated conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:57761 USPATFULL
TITLE: **GLP-1** formulations
INVENTOR(S): Hoffmann, James Arthur, Greenwood, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6358924 B1 20020319
APPLICATION INFO.: US 2000-585181 20000601 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-US25515, filed on 2
Dec 1998

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67600P	19971205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Russel, Jeffrey E.	
LEGAL REPRESENTATIVE:	Stewart, Mark J., Cox, Gregory A.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	490	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 19 OF 26 USPATFULL on STN

TI Mixed micellar drug deliver system and method of preparation
AB Pharmaceutical compositions comprising a macromolecular pharmaceutical agent in micellar form are disclosed. The micelles are formed from an alkali metal alkyl sulfate, and at least one additional micelle-forming compound as described in the specification. An alkali metal salicylate and a pharmaceutically acceptable edetate are also included in the composition. Micelle size ranges between about 1 and 10 nanometers. Methods for making and using the compositions are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:39665 USPATFULL
TITLE: Mixed micellar drug deliver system and method of preparation
INVENTOR(S): Modi, Pankaj, Ancaster, CANADA
PATENT ASSIGNEE(S): Generex Pharmaceuticals Incorporated, Toronto, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6350458	B1	20020226
APPLICATION INFO.:	US 2000-543988		20000406 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-386285, filed on 31 Aug 1999 Continuation-in-part of Ser. No. US 1998-216733, filed on 21 Dec 1998 Continuation-in-part of Ser. No. US 1998-21114, filed on 10 Feb 1998, now patented, Pat. No. US 6017545		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Ware, Todd D		
LEGAL REPRESENTATIVE:	Anderson, Debra Z., Eckert Seamans Cherin & Mellott, LLC		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	1182		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 20 OF 26 USPATFULL on STN

TI Pressurized container having an aerosolized pharmaceutical composition
AB A pharmaceutical composition solubilized in a propellant that can be administered buccally or to the lungs using a metered dose dispenser is provided. The composition comprises a pharmaceutical agent; glycerin and/or polyglycerin; phenol and/or methyl phenol; and

at least one absorption enhancing compound. A pressurized container with the composition and a methods of making the composition are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:39640 USPATFULL
TITLE: Pressurized container having an aerosolized pharmaceutical composition
INVENTOR(S): Modi, Pankaj, Ancaster, CANADA
PATENT ASSIGNEE(S): Generex Pharmaceuticals Incorporated, Ontario, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6350432	B1	20020226
APPLICATION INFO.:	US 1999-272563		19990319 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Bawa, Raj		
LEGAL REPRESENTATIVE:	Anderson, Debra Z., Eckert Seamans Cherin & Mellott, LLC		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	765		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 21 OF 26 USPATFULL on STN

TI Pressurized container having an aerosolized pharmaceutical composition
AB A pressurized container with an aerosol pharmaceutical **formulation**, and a process for making the **formulation**, are provided. The **formulation** comprises a pharmaceutical agent, a phenol, **glycerin** or polyglycerin, and an additional ingredient such as an alkali metal alkyl sulfate, polidocanol alkyl ether or the like. The **formulation** is placed in the pressurized container, which is then charged with a propellant. A method of treating a medical condition, by spraying the **formulation** into the mouth or lungs, is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:202183 USPATFULL
TITLE: Pressurized container having an aerosolized pharmaceutical composition
INVENTOR(S): Modi, Pankaj, Ancaster, Canada
PATENT ASSIGNEE(S): Generex Pharmaceuticals, Inc., Ontario, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6315984	B1	20011113
APPLICATION INFO.:	US 1999-388344		19990903 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-272563, filed on 19 Mar 1999.		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Bawa, Raj		
LEGAL REPRESENTATIVE:	Anderson, Debra Z. Eckert Seamans Cherin & Mellott, LLC		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
LINE COUNT:	891		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 22 OF 26 USPATFULL on STN

TI Aerosol pharmaceutical **formulation** for pulmonary and nasal delivery
AB An aerosol pharmaceutical **formulation** for pulmonary and nasal delivery is provided. The **formulation** comprises a pharmaceutical agent, water, a phenol and a propellant. Optionally, an excipient such as **glycerin** or polyglycerin, lysine or polylysine, or other salts, flavoring or coloring agents, protease inhibitors or stabilizers can be added. A method of administering the **formulation** with a metered dose dispenser, and a dispenser containing the **formulation** are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:162828 USPATFULL
TITLE: Aerosol pharmaceutical **formulation** for pulmonary and nasal delivery
INVENTOR(S): Modi, Pankaj, Ancaster, Canada
PATENT ASSIGNEE(S): Generex Pharmaceuticals, Inc., Ontario, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6294153	B1	20010925
APPLICATION INFO.:	US 1999-397102		19990916 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Bawa, Raj		
LEGAL REPRESENTATIVE:	Anderson, Debra Z. Eckert Seamens Cherin & Mellott, LLC		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
LINE COUNT:	504		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 23 OF 26 USPATFULL on STN

TI Prolonged delivery of peptides
AB There are disclosed methods for the treatment of non-insulin dependent **diabetes** mellitus in a mammal comprising the prolonged administration of **GLP-1** (7-37), and related peptides. Also disclosed are compositions to prolong the administration of the peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:147935 USPATFULL
TITLE: Prolonged delivery of peptides
INVENTOR(S): Kim, Yesook, New York, NY, United States
Lambert, William J., New York, NY, United States
Qi, Hong, New York, NY, United States
Gelfand, Robert A, New York, NY, United States
Geoghegan, Kieran F., New York, NY, United States
Danley, Dennis E., New York, NY, United States
PATENT ASSIGNEE(S): Scios, Inc., Sunnyvale, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6284727	B1	20010904
APPLICATION INFO.:	US 1995-472349		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-181655, filed on 25 Jan 1994, now abandoned Continuation-in-part of Ser. No. US 1993-44133, filed on 7 Apr 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Huff, Sheela		
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox P.L.L.C.		

NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2815
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 24 OF 26 USPATFULL on STN
TI **GLUCAGON-LIKE PEPTIDE-1 CRYSTALS**
AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of **glucagon-like peptide** -1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating **diabetes**, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:134217 USPATFULL
TITLE: **GLUCAGON-LIKE PEPTIDE-1 CRYSTALS**
INVENTOR(S): HERMELING, RONALD NORBERT, INDIANAPOLIS, IN, United States
HOFFMANN, JAMES ARTHUR, GREENWOOD, IN, United States
NARASIMHAN, CHAKAVARTHY, CARMEL, IN, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014666	A1	20010816
	US 6380357	B2	20020430
APPLICATION INFO.:	US 1998-209799	A1	19981211 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROBERT A CONRAD, ELI LILLY AND COMPANY, PATENT DIVISION/RSM, LILLY CORPORATE CENTER, INDIANAPOLIS, IN, 46285		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1106		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 25 OF 26 USPATFULL on STN
TI Transepithelial delivery **GLP-1** derivatives
AB The present invention relates to a new **formulation** comprising a stabilized **GLP-1** compound, such as an analog, fragment or derivative thereof for delivery across pulmonary tissue in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:128841 USPATFULL
TITLE: Transepithelial delivery **GLP-1** derivatives
INVENTOR(S): Anderson, Keith, San Diego, CA, United States
Agerso, Henrik, Fredensborg, Denmark

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001012829	A1	20010809
APPLICATION INFO.:	US 2001-757788	A1	20010110 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-30	20000111
	US 2000-177002P	20000119 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Novo Nordisk of North America, Inc., Suite 6400, 405	

Lexington Avenue, New York, NY, 10017

NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1254
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 26 OF 26 USPATFULL on STN

TI Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
AB A mixed liposome pharmaceutical composition with multilamellar vesicles is provided. The vesicles are comprised of a pharmaceutical agent, membrane-mimetic amphiphiles and various phospholipids. A method of making the composition using high speed mixing of the amphiphiles and phospholipids is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:125964 USPATFULL
TITLE: Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
INVENTOR(S): Modi, Pankaj, Ancaster, Canada
PATENT ASSIGNEE(S): Generex Pharmaceuticals Inc., Toronto, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6271200	B1	20010807
APPLICATION INFO.:	US 1999-397701		19990916 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Wang, Andrew		
ASSISTANT EXAMINER:	Zara, Joe		
LEGAL REPRESENTATIVE:	Anderson, Debra Z. Eckert Seamans Cherin & Mellott, LLC		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	26		
LINE COUNT:	868		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 05:23:34 ON 11 FEB 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, HCAPLUS, BIOSIS, BIOTECHDS' ENTERED AT 05:34:13 ON 11 FEB 2006

L1 4 S SOLUTION FORMULATION AND SHELF STABLE
L2 27364 S GLP OR (GLUCAGON-LIKE-PEPTIDE)
L3 1 S L2 AND L1
L4 1968 S L2 AND FORMULATION
L5 1528 S L4 AND SOLUTION
L6 0 S L5 AND SUBSTITUTION
L7 4 S L5 AND (GLP ANALOG)
L8 1086 S L5 AND DIABETES
L9 974 S L8 AND TREATMENT
L10 3 S L9 AND AMIDE FORMS
E BRADER, M/AU
L11 256 S L8 AND PRESERVATIVE
L12 2 S L11 AND (TONICITY MODIFIER)
L13 111 S L11 AND GLYCERIN
L14 26 S L13 AND (M-CRESOL)

=> s l13 and TRIS

L15 73 L13 AND TRIS

=> s l15 and (basic pH)
L16 5 L15 AND (BASIC PH)

=> d l16 ti abs ibib tot

L16 ANSWER 1 OF 5 USPATFULL on STN

TI Pre-mixes of **glp-1** and basal insulin

AB The present invention encompasses pre-mixed formulations comprising a **GLP-1** polypeptide and a basal insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:299841 USPATFULL

TITLE: Pre-mixes of **glp-1** and basal insulin

INVENTOR(S): DeFelippis, Michael Rosario, Carmel, IN, UNITED STATES

DiMarchi, Richard Dennis, Carmel, IN, UNITED STATES

Ng, Kingman, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004235710	A1	20041125
APPLICATION INFO.:	US 2004-486333	A1	20040209 (10)
	WO 2002-US21856		20020823

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-60315460	20010828
	US 2002-60385266	20020531
	US 2002-60386061	20020604

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288

NUMBER OF CLAIMS: 36

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 2056

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 2 OF 5 USPATFULL on STN

TI Method for administering insulintropic peptides

AB The claimed invention relates to a method of administering **glucagon-like peptide-1** molecules by inhalation, a method for treating **diabetes** by administering **glucagon-like peptide-1** molecules by inhalation, and a method for treating hyperglycemia by administering **glucagon-like peptide-1** molecules by inhalation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:158101 USPATFULL

TITLE: Method for administering insulintropic peptides

INVENTOR(S): Hughes, Benjamin Lee, Indianapolis, IN, UNITED STATES

Wolff, Ronald Keith, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004120897	A1	20040624
APPLICATION INFO.:	US 2003-732091	A1	20031210 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-383789, filed on 26 Aug 1999, GRANTED, Pat. No. US 6720407		

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1998-98273P 19980828 (60)
US 1998-100012P 19980911 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288,
INDIANAPOLIS, IN, 46206-6288
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 985
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 3 OF 5 USPATFULL on STN

TI Method for administering insulinotropic peptides
AB The claimed invention relates to a method of administering
glucagon-like peptide-1 molecules by
inhalation, a method for treating **diabetes** by administering
glucagon-like peptide-1 molecules by
inhalation, and a method for treating hyperglycemia by administering
glucagon-like peptide-1 molecules by
inhalation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:90699 USPATFULL
TITLE: Method for administering insulinotropic peptides
INVENTOR(S): Hughes, Benjamin Lee, Indianapolis, IN, United States
Wolff, Ronald Keith, Carmel, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6720407	B1	20040413
APPLICATION INFO.:	US 1999-383789		19990826 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-100012P	19980911 (60)
	US 1998-98273P	19980828 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Lukton, David	
LEGAL REPRESENTATIVE:	Cox, Gregory A.	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1011	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 4 OF 5 USPATFULL on STN

TI **Glucagon-like peptide-1** crystals
AB The invention provides individual tetragonal flat rod shaped or
plate-like crystals of **glucagon-like peptide**
-1 related molecules, processes for their preparation, compositions and
methods of use. The crystal preparations exhibit extended time action in
vivo and are useful for treating **diabetes**, obesity and related
conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:65340 USPATFULL
TITLE: **Glucagon-like peptide-1**
crystals
INVENTOR(S): Hermeling, Ronald Norbert, Indianapolis, IN, UNITED

STATES

Hoffmann, James Arthur, Greenwood, IN, UNITED STATES

Narasimhan, Chakravarthy, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045464	A1	20030306
	US 6555521	B2	20030429
APPLICATION INFO.:	US 2001-997792	A1	20011130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-209799, filed on 11 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69728P	19971216 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, DROP CODE 1104, INDIANAPOLIS, IN, 46285	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1128	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L16 ANSWER 5 OF 5 USPATFULL on STN

TI **GLUCAGON-LIKE PEPTIDE-1 CRYSTALS**

AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of **glucagon-like peptide** -1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating **diabetes**, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:134217 USPATFULL
TITLE: **GLUCAGON-LIKE PEPTIDE-1 CRYSTALS**

INVENTOR(S): HERMELING, RONALD NORBERT, INDIANAPOLIS, IN, United States
HOFFMANN, JAMES ARTHUR, GREENWOOD, IN, United States
NARASIMHAN, CHAKAVARTHY, CARMEL, IN, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014666	A1	20010816
	US 6380357	B2	20020430
APPLICATION INFO.:	US 1998-209799	A1	19981211 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROBERT A CONRAD, ELI LILLY AND COMPANY, PATENT DIVISION/RSM, LILLY CORPORATE CENTER, INDIANAPOLIS, IN, 46285		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1106		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

=> d his

(FILE 'HOME' ENTERED AT 05:23:34 ON 11 FEB 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, HCAPLUS, BIOSIS,

BIOTECHDS' ENTERED AT 05:34:13 ON 11 FEB 2006

L1 4 S SOLUTION FORMULATION AND SHELF STABLE
L2 27364 S GLP OR (GLUCAGON-LIKE-PEPTIDE)
L3 1 S L2 AND L1
L4 1968 S L2 AND FORMULATION
L5 1528 S L4 AND SOLUTION
L6 0 S L5 AND SUBSTITUTION
L7 4 S L5 AND (GLP ANALOG)
L8 1086 S L5 AND DIABETES
L9 974 S L8 AND TREATMENT
L10 3 S L9 AND AMIDE FORMS
E BRADER, M/AU
L11 256 S L8 AND PRESERVATIVE
L12 2 S L11 AND (TONICITY MODIFIER)
L13 111 S L11 AND GLYCERIN
L14 26 S L13 AND (M-CRESOL)
L15 73 S L13 AND TRIS
L16 5 S L15 AND (BASIC PH)

=> s l15 ti abs ibib 1-15

MISSING OPERATOR L15 TI

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d l15 ti abs ibib 1-15

L15 ANSWER 1 OF 73 USPATFULL on STN

TI Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof

AB Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.

ACCESSION NUMBER: 2006:21042 USPATFULL

TITLE: Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof

INVENTOR(S): Radhakrishnan, Balasingam, Chapel Hill, NC, UNITED STATES

Aggarwal, Diti, Raleigh, NC, UNITED STATES

Ferro, Michelle, Raleigh, NC, UNITED STATES

James, Kenneth D., Mebane, NC, UNITED STATES

Malkar, Navdeep B., Cary, NC, UNITED STATES

Miller, Mark A., Raleigh, NC, UNITED STATES

Pavliv, Leo, Morrisville, NC, UNITED STATES

Polowy, Karen, Raleigh, NC, UNITED STATES

Puskas, Monica, Spring Hope, NC, UNITED STATES

Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006018874	A1	20060126
APPLICATION INFO.:	US 2005-184528	A1	20050719 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-589058P	20040719 (60)
	US 2004-619153P	20041015 (60)
	US 2004-632578P	20041202 (60)
	US 2005-655838P	20050224 (60)
	US 2005-655803P	20050224 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MOORE & VAN ALLEN PLLC, P.O. BOX 13706, Research Triangle Park, NC, 27709, US	
NUMBER OF CLAIMS:	111	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	42 Drawing Page(s)	
LINE COUNT:	5677	

L15 ANSWER 2 OF 73 USPATFULL on STN

TI Dipeptidyl peptidase inhibitors

AB Compounds, pharmaceutical compositions, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound of the formula: ##STR1## wherein R.sub.2 is amino (C.sub.1-6)alkyl, hetero(C.sub.3-12)cycloalkyl, hetero(C.sub.4-12)bicycloalkyl, heteroaryl, or cyano; and W, X, Y, Z, R.sub.1, R.sub.5 and R.sub.7 are as defined herein.

ACCESSION NUMBER: 2006:16387 USPATFULL
 TITLE: Dipeptidyl peptidase inhibitors
 INVENTOR(S): Feng, Jun, Carlsbad, CA, UNITED STATES
 Gwaltney, Stephen L., San Diego, CA, UNITED STATES
 Lam, Betty, Spring Valley, CA, UNITED STATES
 Zhang, Zhiyuan, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006014764	A1	20060119
APPLICATION INFO.:	US 2005-183335	A1	20050715 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-588577P	20040716 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TAKEDA SAN DIEGO, INC., 10410 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121, US	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3732	

L15 ANSWER 3 OF 73 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:15872 USPATFULL

TITLE: Albumin fusion proteins
INVENTOR(S): Haseltine, William A., Washington, DC, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006014254	A1	20060119
APPLICATION INFO.:	US 2005-175690	A1	20050707 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2004-US1369, filed on 20 Jan 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-441305P	20030122 (60)
	US 2003-453201P	20030311 (60)
	US 2003-467222P	20030502 (60)
	US 2003-472816P	20030523 (60)
	US 2003-476267P	20030606 (60)
	US 2003-505172P	20030924 (60)
	US 2003-506746P	20030930 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT.,
14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US

NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 17653
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 4 OF 73 USPATFULL on STN
TI Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
AB Compositions and methods of using the same for the treatment of **diabetes** and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2006:4523 USPATFULL
TITLE: Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
INVENTOR(S): Fine, Stuart A., Northbrook, IL, UNITED STATES
Kinsella, Kevin J., La Jolla, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006003981	A1	20060105
APPLICATION INFO.:	US 2005-142807	A1	20050601 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2005-42354, filed on 25 Jan 2005, PENDING Continuation of Ser. No. US 2001-787325, filed on 4 Jun 2001, GRANTED, Pat. No. US 6852760 A 371 of International Ser. No. WO 1999-US21377, filed on 17 Sep 1999 Continuation-in-part of Ser. No. US 1998-156102, filed on 17 Sep 1998, GRANTED, Pat. No. US 6376549		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-126489P	19990326 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1-96
LINE COUNT: 2773
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 73 USPATFULL on STN
TI Prolonged delivery of peptides
AB There are disclosed methods for the treatment of non-insulin dependent **diabetes** mellitus in a mammal comprising the prolonged administration of **GLP-1** (7-37), and related peptides. Also disclosed are compositions to prolong the administration of the peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:4460 USPATFULL
TITLE: Prolonged delivery of peptides
INVENTOR(S): Kim, Yesook, Branford, CT, UNITED STATES
Lambert, William J., East Lyme, CT, UNITED STATES
Qi, Hong, East Lyme, CT, UNITED STATES
Gelfand, Robert A., Madison, CT, UNITED STATES
Geoghegan, Kieran F., Mystic, CT, UNITED STATES
Danley, Dennis E., Waterford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006003918	A1	20060105
APPLICATION INFO.:	US 2004-6990	A1	20041207 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-943084, filed on 31 Aug 2001, GRANTED, Pat. No. US 6828303 Continuation of Ser. No. US 1995-472349, filed on 7 Jun 1995, GRANTED, Pat. No. US 6284727 Continuation of Ser. No. US 1994-181655, filed on 25 Jan 1994, ABANDONED Continuation-in-part of Ser. No. US 1993-44133, filed on 7 Apr 1993, ABANDONED		

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 12531 HIGH BLUFF DRIVE, SUITE 100, SAN DIEGO, CA, 92130-2040, US

NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 2264

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 6 OF 73 USPATFULL on STN
TI Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
AB Compositions and methods of using the same for the treatment of **diabetes** and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:324882 USPATFULL
TITLE: Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
INVENTOR(S): Fine, Stuart A., Northbrook, IL, UNITED STATES
Kinsella, Kevin J., La Jolla, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2005282794 A1 20051222
 APPLICATION INFO.: US 2005-141265 A1 20050531 (11)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 2005-42354, filed on 25 Jan 2005, PENDING Continuation of Ser. No. US 2001-787325, filed on 4 Jun 2001, GRANTED, Pat. No. US 6852760 A 371 of International Ser. No. WO 1999-US21377, filed on 17 Sep 1999 Continuation-in-part of Ser. No. US 1998-156102, filed on 17 Sep 1998, GRANTED, Pat. No. US 6376549

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-126489P	19990326 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US	
NUMBER OF CLAIMS:	96	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2949	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 7 OF 73 USPATFULL on STN
 TI Dipeptidyl peptidase inhibitors
 AB Compounds, pharmaceutical compositions, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound of the formula: ##STR1## wherein the substituents are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ACCESSION NUMBER: 2005:313146 USPATFULL
 TITLE: Dipeptidyl peptidase inhibitors
 INVENTOR(S): Feng, Jun, Carlsbad, CA, UNITED STATES
 Gwaltney, Stephen L., San Diego, CA, UNITED STATES
 Wallace, Michael B., San Diego, CA, UNITED STATES
 Zhang, Zhiyuan, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005272765	A1	20051208
APPLICATION INFO.:	US 2005-145579	A1	20050603 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-577144P	20040604 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TAKEDA SAN DIEGO, INC., 10410 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121, US	
NUMBER OF CLAIMS:	64	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	4935	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 8 OF 73 USPATFULL on STN
 TI Dipeptidyl peptidase inhibitors
 AB Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising: ##STR1## wherein M is N or CR.sub.4; Q.sup.1 and Q.sup.2 are each independently selected from the group consisting of CO, SO, SO.sub.2, and C.dbd.NR.sub.9; and each L, X, R.sub.1, R.sub.2, and R.sub.3 are as

defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:299602 USPATFULL
TITLE: Dipeptidyl peptidase inhibitors
INVENTOR(S): Feng, Jun, Carlsbad, CA, UNITED STATES
Gwaltney, Stephen L., San Diego, CA, UNITED STATES
Stafford, Jeffrey A., San Diego, CA, UNITED STATES
Zhang, Zhiyuan, San Diego, CA, UNITED STATES
Elder, Bruce J., Wynantskill, NY, UNITED STATES
Isbester, Paul K., Castleton, NY, UNITED STATES
Palmer, Grant J., Clifton Park, NY, UNITED STATES
Salsbury, Jonathon S., Albany, NY, UNITED STATES
Ulysse, Luckner G., Albany, NY, UNITED STATES
PATENT ASSIGNEE(S): Takeda San Diego, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005261271	A1	20051124
APPLICATION INFO.:	US 2005-80992	A1	20050315 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-553571P	20040315 (60)
	US 2004-629524P	20041118 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TAKEDA SAN DIEGO, INC., 10410 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121, US	
NUMBER OF CLAIMS:	161	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	5390	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 9 OF 73 USPATFULL on STN

TI Compositions for treatment with **glucagon-like peptide**, and methods of making and using the same
AB In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and **GLP-1**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:298594 USPATFULL
TITLE: Compositions for treatment with **glucagon-like peptide**, and methods of making and using the same
INVENTOR(S): Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005260259	A1	20051124
APPLICATION INFO.:	US 2005-112879	A1	20050422 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-564710P	20040423 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	

LINE COUNT: 3100
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 10 OF 73 USPATFULL on STN

TI Nitrogen-containing compounds

AB A compound represented by formula (I); ##STR1## wherein ring A represents a nitrogen containing heterocyclic ring, ring B represents a 5-membered heterocyclic ring which may have substituents, R represents a hydrogen atom or cyano and the other symbols represent as described in the specification; or a salt thereof. The compound represented by formula (I) has an inhibitory activity of DPP-IV, and therefore is useful as a preventive and/or treatment agent for type 2 **diabetes** mellitus, obesity, autoimmune disease, cancer metastasis, AIDS virus infection, dermatosis, prostatic hypertrophy and the like

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:293617 USPATFULL
TITLE: Nitrogen-containing compounds
INVENTOR(S): Nakai, Hisao, Mishima-gun, JAPAN
Kondo, Takashi, Mishima-gun, JAPAN
Yamamoto, Susumu, Mishima-gun, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005256166	A1	20051117
APPLICATION INFO.:	US 2003-525061	A1	20030818 (10)
	WO 2003-JP10401		20030818
			20050218 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2003-2002238673	20020819
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2852	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 11 OF 73 USPATFULL on STN

TI Body weight gain inhibitors

AB An agent for inhibiting body weight gain derived from a PPAR γ agonist-like substance, which contains a PPAR δ agonist-like substance, is useful for the treatment of **diabetes** and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:275290 USPATFULL
TITLE: Body weight gain inhibitors
INVENTOR(S): Sugiyama, Yasuo, Kawanishi-shi, JAPAN
Odaka, Hiroyuki, Kobe-shi, JAPAN
Kimura, Hiroyuki, Osaka, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239854	A1	20051027
APPLICATION INFO.:	US 2005-168357	A1	20050629 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-129704, filed on 9 May 2002, ABANDONED A 371 of International Ser. No. WO 2000-JP7879, filed on 9 Nov 2000		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-320319	19991110
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021, US	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1-10	
LINE COUNT:	1887	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L15 ANSWER 12 OF 73 USPATFULL on STN

TI Combinations of chromium or vanadium with antidiabetics
 AB Compositions and methods of using the same for the treatment of
diabetes and other disorders of glucose metabolism are provided.
 Compositions may include an anti-diabetic agent and one or more of a
 bioavailable source of chromium and vanadium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:268627 USPATFULL
 TITLE: Combinations of chromium or vanadium with antidiabetics
 INVENTOR(S): Fine, Stuart A., Northbrook, IL, UNITED STATES
 Kinsella, Kevin J., La Jolla, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005233947	A1	20051020
APPLICATION INFO.:	US 2005-88273	A1	20050323 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2005-42354, filed on 25 Jan 2005, PENDING Continuation of Ser. No. US 2001-787325, filed on 4 Jun 2001, GRANTED, Pat. No. US 6852760 A 371 of International Ser. No. WO 1999-US21377, filed on 17 Sep 1999 Continuation-in-part of Ser. No. US 1998-156102, filed on 17 Sep 1998, GRANTED, Pat. No. US 6376549		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1-96		
LINE COUNT:	2752		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L15 ANSWER 13 OF 73 USPATFULL on STN

TI Combinations of chromium or vanadium with antidiabetics for glucose
 metabolism disorders
 AB Compositions and methods of using the same for the treatment of
diabetes and other disorders of glucose metabolism are provided.
 Compositions may include an anti-diabetic agent and one or more of a
 bioavailable source of chromium and vanadium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:268626 USPATFULL
 TITLE: Combinations of chromium or vanadium with antidiabetics
 for glucose metabolism disorders
 INVENTOR(S): Fine, Stuart A., Northbrook, IL, UNITED STATES
 Kinsella, Kevin J., La Jolla, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2005233946 A1 20051020
APPLICATION INFO.: US 2005-88272 A1 20050323 (11)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2005-42354, filed on 25 Jan 2005, PENDING Continuation of Ser. No. US 2001-787325, filed on 4 Jun 2001, GRANTED, Pat. No. US 6852760 A 371 of International Ser. No. WO 1999-US21377, filed on 17 Sep 1999, Continuation-in-part of Ser. No. US 1998-156102, filed on 17 Sep 1998, GRANTED, Pat. No. US 6376549
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1-96
LINE COUNT: 2734
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 14 OF 73 USPATFULL on STN

TI Benzimidazole derivative and use thereof
AB The present invention relates to a compound represented by the formula (I) ##STR1## wherein R.sup.1 is a group represented by the formula ##STR2## wherein R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently a hydrogen atom or a C.sub.1-6 alkyl, or a salt thereof. The compound of the present invention is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like, and metabolic diseases such as **diabetes** and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:215593 USPATFULL
TITLE: Benzimidazole derivative and use thereof
INVENTOR(S): Kuroita, Takanobu, Osaka, JAPAN
Sakamoto, Hiroki, Amagasaki-shi, JAPAN
Ojima, Mami, Amagasaki-shi, JAPAN
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005187269	A1	20050825
APPLICATION INFO.:	US 2005-31057	A1	20050107 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2004-48928	20040225
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069, US	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1368	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 15 OF 73 USPATFULL on STN

TI Combinations of chromium/or vanadium with antidiabetics for glucose metabolism disorders
AB Compositions and methods of using the same for the treatment of **diabetes** and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:215468 USPATFULL

TITLE: Combinations of chromium or vanadium with antidiabetics
for glucose metabolism disorders

INVENTOR(S): Fine, Stuart A., Northbrook, IL, UNITED STATES
Kinsella, Kevin J., La Jolla, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005187144	A1	20050825
APPLICATION INFO.:	US 2005-42354	A1	20050125 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-787325, filed on 4 Jun 2001, GRANTED, Pat. No. US 6852760 A 371 of International Ser. No. WO 1999-US21377, filed on 17 Sep 1999 Continuation-in-part of Ser. No. US 1998-156102, filed on 17 Sep 1998, GRANTED, Pat. No. US 6376549		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US		
NUMBER OF CLAIMS:	39		
EXEMPLARY CLAIM:	1-96		
LINE COUNT:	2744		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Refine Search

Search Results -

Terms	Documents
L12 and (GLP-1(7-34))	9

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L13

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Saturday, February 11, 2006

[Printable Copy](#)

[Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L13</u>	L12 and (GLP-1(7-34))	9	<u>L13</u>
<u>L12</u>	L10 and Tris	9	<u>L12</u>
<u>L11</u>	L3 and l1	0	<u>L11</u>
<u>L10</u>	L3 and l2	13	<u>L10</u>
<u>L9</u>	L3 and l2	13	<u>L9</u>
<u>L8</u>	L7 and Tris	1	<u>L8</u>
<u>L7</u>	6573237.pn.	1	<u>L7</u>
<u>L6</u>	L4 and (pH)	1	<u>L6</u>
<u>L5</u>	L4 and TRIS	0	<u>L5</u>
<u>L4</u>	5545618.pn.	1	<u>L4</u>
<u>L3</u>	(GLP or glucagon-like-peptide)	987	<u>L3</u>
<u>L2</u>	hoffmann.in.	2576	<u>L2</u>
<u>L1</u>	brader.in.	71	<u>L1</u>

END OF SEARCH HISTORY

Hit List

2-11-2006

[First Hit](#) [Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 10 of 13 returned.

☐ 1. Document ID: US 6949515 B2

L10: Entry 1 of 13

File: USPT

Sep 27, 2005

US-PAT-NO: 6949515

DOCUMENT-IDENTIFIER: US 6949515 B2

TITLE: Effectors of dipeptidyl peptidase IV for topical use

DATE-ISSUED: September 27, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demuth; Hans-Ulrich	Halle/Saale			DE
Hoffmann; Torsten	Halle/Saale			DE
Schlenzig; Dagmar	Halle/Saale			DE
Heiser; Ulrich	Halle/Saale			DE

US-CL-CURRENT: 514/19; 424/78.02, 424/94.63, 514/183, 544/141, 548/200, 548/400, 548/535

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 2. Document ID: US 6946480 B2

L10: Entry 2 of 13

File: USPT

Sep 20, 2005

US-PAT-NO: 6946480

DOCUMENT-IDENTIFIER: US 6946480 B2

TITLE: Glutaminyl based DPIV inhibitors

DATE-ISSUED: September 20, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demuth; Hans-Ulrich	D-06114 Halle/Saale			DE
Hoffmann; Torsten	D-06114 Halle/Saale			DE
Heiser; Ulrich	D-06108 Halle/Saale			DE

US-CL-CURRENT: 514/365; 514/423, 548/200, 548/531

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 3. Document ID: US 6767887 B1

L10: Entry 3 of 13

File: USPT

Jul 27, 2004

US-PAT-NO: 6767887

DOCUMENT-IDENTIFIER: US 6767887 B1

**** See image for Certificate of Correction ****

TITLE: Exendin analogues, processes for their preparation and medicaments containing them

DATE-ISSUED: July 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hoffmann; Eike	Viernheim			DE
Goke; Rudiger	Marburg			DE
Goke; Burkhard-Johannes	Marburg			DE

US-CL-CURRENT: 514/2; 514/866, 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

☐ 4. Document ID: US 6703365 B2

L10: Entry 4 of 13

File: USPT

Mar 9, 2004

US-PAT-NO: 6703365

DOCUMENT-IDENTIFIER: US 6703365 B2

TITLE: Glucagon-like insulintropic peptides, compositions and methods

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Galloway; John A.	Cambridge	MA		
Hoffmann; James A.	Greenwood	IN		

US-CL-CURRENT: 514/12; 514/2, 514/866, 530/308, 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

☐ 5. Document ID: US 6555521 B2

L10: Entry 5 of 13

File: USPT

Apr 29, 2003

US-PAT-NO: 6555521

DOCUMENT-IDENTIFIER: US 6555521 B2

TITLE: Glucagon-like peptide-1 crystals

DATE-ISSUED: April 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hermeling; Ronald Norbert	Indianapolis	IN		
Hoffmann; James Arthur	Greenwood	IN		
Narasimhan; Chakravarthy	Carmel	IN		

US-CL-CURRENT: 514/12; 514/21, 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

☐ 6. Document ID: US 6388053 B1

L10: Entry 6 of 13

File: USPT

May 14, 2002

US-PAT-NO: 6388053

DOCUMENT-IDENTIFIER: US 6388053 B1

TITLE: Glucagon-like insulintropic peptides, compositions and methods

DATE-ISSUED: May 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Galloway; John A.	Cambridge	MA		
Hoffmann; James A.	Greenwood	IN		

US-CL-CURRENT: 530/308; 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

☐ 7. Document ID: US 6380357 B2

L10: Entry 7 of 13

File: USPT

Apr 30, 2002

US-PAT-NO: 6380357

DOCUMENT-IDENTIFIER: US 6380357 B2

**** See image for Certificate of Correction ****

TITLE: Glucagon-like peptide-1 crystals

DATE-ISSUED: April 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hermeling; Ronald Norbert	Indianapolis	IN		
Hoffmann; James Arthur	Greenwood	IN		
Narasimhan; Chakravarthy	Carmel	IN		

US-CL-CURRENT: 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

☐ 8. Document ID: US 6358924 B1

L10: Entry 8 of 13

File: USPT

Mar 19, 2002

US-PAT-NO: 6358924

DOCUMENT-IDENTIFIER: US 6358924 B1

TITLE: GLP-1 formulations

DATE-ISSUED: March 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

US-CL-CURRENT: 514/12; 514/21, 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-----

☐ 9. Document ID: US 6319893 B1

L10: Entry 9 of 13

File: USPT

Nov 20, 2001

US-PAT-NO: 6319893

DOCUMENT-IDENTIFIER: US 6319893 B1

TITLE: Raising blood sugar level in hypoglycemic mammals by administering inhibitors of dipeptidyl peptidase IV

DATE-ISSUED: November 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demuth; Hans-Ulrich	Halle/Saale			DE
Hoffmann; Torsten	Halle/Saale			DE
Kuhn-Wache; Kerstin	Halle/Saale			DE
Rosche; Fred	Halle/Saale			DE

US-CL-CURRENT: 514/2; 424/130.1, 514/19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-----

☐ 10. Document ID: US 6133235 A

L10: Entry 10 of 13

File: USPT

Oct 17, 2000

US-PAT-NO: 6133235

DOCUMENT-IDENTIFIER: US 6133235 A

**** See image for Certificate of Correction ****

TITLE: Glucagon-like insulintropic peptides compositions and methods

DATE-ISSUED: October 17, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Galloway; John A.	Indianapolis	IN		
Hoffmann; James A.	Greenwood	IN		

US-CL-CURRENT: 514/12; 514/2, 514/866, 530/308, 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-----

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms	Documents
L3 and L2	13

Display Format:

CIT

Change Format

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Refine Search

Search Results -

Terms	Documents
L10 and Tris	9

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L12

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Saturday, February 11, 2006 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L12</u>	L10 and Tris	9	<u>L12</u>
<u>L11</u>	L3 and l1	0	<u>L11</u>
<u>L10</u>	L3 and l2	13	<u>L10</u>
<u>L9</u>	L3 and l2	13	<u>L9</u>
<u>L8</u>	L7 and Tris	1	<u>L8</u>
<u>L7</u>	6573237.pn.	1	<u>L7</u>
<u>L6</u>	L4 and (pH)	1	<u>L6</u>
<u>L5</u>	L4 and TRIS	0	<u>L5</u>
<u>L4</u>	5545618.pn.	1	<u>L4</u>
<u>L3</u>	(GLP or glucagon-like-peptide)	987	<u>L3</u>
<u>L2</u>	hoffmann.in.	2576	<u>L2</u>
<u>L1</u>	brader.in.	71	<u>L1</u>

END OF SEARCH HISTORY

Hit List

[First Hit](#) [Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 9 of 9 returned.

☐ 1. Document ID: US 6767887 B1

L12: Entry 1 of 9

File: USPT

Jul 27, 2004

US-PAT-NO: 6767887

DOCUMENT-IDENTIFIER: US 6767887 B1

**** See image for Certificate of Correction ****

TITLE: Exendin analogues, processes for their preparation and medicaments containing them

DATE-ISSUED: July 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Hoffmann</u> ; Eike	Viernheim			DE
Goke; Rudiger	Marburg			DE
Goke; Burkhard-Johannes	Marburg			DE

US-CL-CURRENT: 514/2; 514/866, 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	-----	-----------	-----

☐ 2. Document ID: US 6703365 B2

L12: Entry 2 of 9

File: USPT

Mar 9, 2004

US-PAT-NO: 6703365

DOCUMENT-IDENTIFIER: US 6703365 B2

TITLE: Glucagon-like insulintropic peptides, compositions and methods

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Galloway; John A.	Cambridge	MA		
<u>Hoffmann</u> ; James A.	Greenwood	IN		

US-CL-CURRENT: 514/12; 514/2, 514/866, 530/308, 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	-----	-----------	-----

☐ 3. Document ID: US 6555521 B2

L12: Entry 3 of 9

File: USPT

Apr 29, 2003

US-PAT-NO: 6555521

DOCUMENT-IDENTIFIER: US 6555521 B2

TITLE: Glucagon-like peptide-1 crystals

DATE-ISSUED: April 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hermeling; Ronald Norbert	Indianapolis	IN		
<u>Hoffmann</u> ; James Arthur	Greenwood	IN		
Narasimhan; Chakravarthy	Carmel	IN		

US-CL-CURRENT: 514/12; 514/21, 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 4. Document ID: US 6388053 B1

L12: Entry 4 of 9

File: USPT

May 14, 2002

US-PAT-NO: 6388053

DOCUMENT-IDENTIFIER: US 6388053 B1

TITLE: Glucagon-like insulintropic peptides, compositions and methods

DATE-ISSUED: May 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Galloway; John A.	Cambridge	MA		
<u>Hoffmann</u> ; James A.	Greenwood	IN		

US-CL-CURRENT: 530/308; 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 5. Document ID: US 6380357 B2

L12: Entry 5 of 9

File: USPT

Apr 30, 2002

US-PAT-NO: 6380357

DOCUMENT-IDENTIFIER: US 6380357 B2

**** See image for Certificate of Correction ****

TITLE: Glucagon-like peptide-1 crystals

DATE-ISSUED: April 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hermeling; Ronald Norbert	Indianapolis	IN		
<u>Hoffmann</u> ; James Arthur	Greenwood	IN		
Narasimhan; Chakravarthy	Carmel	IN		

US-CL-CURRENT: 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 6. Document ID: US 6319893 B1

L12: Entry 6 of 9

File: USPT

Nov 20, 2001

US-PAT-NO: 6319893

DOCUMENT-IDENTIFIER: US 6319893 B1

TITLE: Raising blood sugar level in hypoglycemic mammals by administering inhibitors of dipeptidyl peptidase IV

DATE-ISSUED: November 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demuth; Hans-Ulrich	Halle/Saale			DE
Hoffmann; Torsten	Halle/Saale			DE
Kuhn-Wache; Kerstin	Halle/Saale			DE
Rosche; Fred	Halle/Saale			DE

US-CL-CURRENT: 514/2; 424/130.1, 514/19

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 7. Document ID: US 6133235 A

L12: Entry 7 of 9

File: USPT

Oct 17, 2000

US-PAT-NO: 6133235

DOCUMENT-IDENTIFIER: US 6133235 A

**** See image for Certificate of Correction ****

TITLE: Glucagon-like insulintropic peptides compositions and methods

DATE-ISSUED: October 17, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Galloway; John A.	Indianapolis	IN		
Hoffmann; James A.	Greenwood	IN		

US-CL-CURRENT: 514/12; 514/2, 514/866, 530/308, 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 8. Document ID: US 5977071 A

L12: Entry 8 of 9

File: USPT

Nov 2, 1999

US-PAT-NO: 5977071

DOCUMENT-IDENTIFIER: US 5977071 A

TITLE: Glucagon-like insulintropic peptides, compositions and methods

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Galloway; John A.	Indianapolis	IN		
Hoffmann; James A.	Greenwood	IN		

US-CL-CURRENT: 514/12; 514/866, 530/308, 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

☐ 9. Document ID: US 5705483 A

L12: Entry 9 of 9

File: USPT

Jan 6, 1998

US-PAT-NO: 5705483

DOCUMENT-IDENTIFIER: US 5705483 A

**** See image for Certificate of Correction ****

TITLE: Glucagon-like insulintropic peptides, compositions and methods

DATE-ISSUED: January 6, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Galloway; John A.	Indianapolis	IN		
Hoffmann; James A.	Greenwood	IN		

US-CL-CURRENT: 514/12; 530/308, 530/324, 977/DIG.1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L10 and Tris	9

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Refine Search

Search Results -

Terms	Documents
L1 and (TRIS)	0

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L3

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, February 08, 2006 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set

DB=USPT; PLUR=YES; OP=OR

<u>L3</u>	L1 and (TRIS)	0	<u>L3</u>
<u>L2</u>	L1 and TRIS	0	<u>L2</u>
<u>L1</u>	6358924.pn.	1	<u>L1</u>

END OF SEARCH HISTORY